| Latest Immupharma Plc News Headlines |
| Date | Time | Source | |
| 11/12/2008 | 2:00AM | UKREG | Grant Award
RNS Number : 9464H
Immupharma PLC
12 November 2008
For Immediate Release 12 November 2008
ImmuPharma awarded grant for developing cancer drug
ImmuPharma PLC (LSE:IMM), ("ImmuPharma or the "Company... More...>> |
| 10/21/2008 | 4:56AM | TFNF | Immupharma says Lupuzor patents granted in US, Japan, Australia
Immupharma Plc. said its Lupuzor patent has
been approved in Japan and Australia and received notice of allowance from the
United States patent office.
The company also said the mechanism of action of Lupuzor has been identified
by researchers working with ImmuPharma at the Centre National de la Recherche
Scientifique... More...>> |
| 10/21/2008 | 4:31AM | UKREG | Patents Granted
RNS Number : 3059G
Immupharma PLC
21 October 2008
For Immediate Release 21 October 2008
LupuzorTM patents allowed in US and approved in Japan, Australia
- other countries expected to follow... More...>> |
| 10/17/2008 | 11:22AM | UKREG | Additional Listing and Total Voting Rights
RNS Number : 1485G
Immupharma PLC
17 October 2008
ImmuPharma PLC (the "Company")
Additional Listing and Total Voting Rights
Following the receipt of notices of exercise of options, application has been made to the London Stock Exchange for the admission of
132,000 new ordinary shares to... More...>> |
| 09/25/2008 | 3:56AM | TFNF | Immupharma H1 pretax loss narrows to 1.45 mln pounds vs 1.54 mln pounds
Immupharma Plc. reported a narrower first-half
pretax loss and said it is in talks with a number of large pharmaceutical and
biotech companies for potential collaborations
The specialist drug discovery and development company also said it is
considering developing some of its assets alone, which would require... More...>> |
| 09/25/2008 | 2:02AM | UKREG | Interim Results
RNS Number : 2638E
Immupharma PLC
25 September 2008
For Immediate Release 25 September
2008
ImmuPharma plc
Interim Results Announcement
For the six months ended 30 June 2008
ImmuPharma... More...>> |
| 08/18/2008 | 3:32AM | TFNF | Lipoxen names business development director Peter Laing chief operating officer
Lipoxen Plc. said it has appointed business
development director Peter Laing as chief operating officer.
The biopharmaceutical company specialising in the development of high value
differentiated biologicals, vaccines and oncology drugs, has also appointed Ajay
K. Agrawal as head of business development... More...>> |
| 08/05/2008 | 10:44AM | UKREG | AGM Result
RNS Number : 7058A
Immupharma PLC
05 August 2008
For Immediate Release 5 August 2008
AGM Statement
ImmuPharma plc (LSE:IMM), the specialist pharmaceutical discovery and development company, held its AGM earlier today and is pleased to
announce that all resolutions... More...>> |
| 07/10/2008 | 2:30AM | TFNF | ImmuPharma raises 1.1 mln pounds after placing 1.9 mln shares at 60 pence/share
ImmuPharma Plc, the specialist drug discovery
and development company, has raised about 1.1 million pounds principally from
institutional investors based in Switzerland through a placing of 1,876,000
shares at a price of 60 pence/share.
The placing follows a fundraising announced on July 2, meaning that... More...>> |
| 07/10/2008 | 2:01AM | UKREG | Second Placing
RNS Number : 7451Y
Immupharma PLC
10 July 2008
For Immediate Release 10 July 2008
ImmuPharma raises additional £1.1 million (CHF 2.2 million) to advance development programmes
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company... More...>> |
| 07/02/2008 | 3:03AM | TFNF | Immupharma first toxicology study for Lupuzor Lupus product judged successful
ImmuPharma Plc., the specialist drug discovery
company, said its Lupuzor treatment for Lupus has completed the first leg of its
mandatory long term toxicology study.
The first study showed no clinical or laboratory findings to suggest any
safety issues, while an interim analysis of the second study for... More...>> |
| 07/02/2008 | 2:30AM | TFNF | Immupharma placing raises 1.6 million pounds to further clinical projects
ImmuPharma Plc., a specialist drug discovery
company, has raised 1.6 million pounds in a placing with institutional investors
to further its drug development programmes.
The company issued 2,697,034 new ordinary shares of 10 pence each at a price
of 60 pence per share, Immupharma said.
The funds will... More...>> |
| 07/02/2008 | 2:30AM | UKREG | Toxicology study
RNS Number : 0898Y
Immupharma PLC
02 July 2008
For Immediate Release 2 July 2008
ImmuPharma PLC
Long term toxicology studies confirmed the safety of LupuzorTM
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company... More...>> |
| 07/02/2008 | 2:01AM | UKREG | Fund Raising
RNS Number : 0897Y
Immupharma PLC
02 July 2008
For Immediate Release 2 July 2008
ImmuPharma plc
ImmuPharma raises £1.6 million to advance development programmes
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces... More...>> |
| 06/30/2008 | 10:00AM | UKREG | Annual Report and Accounts
RNS Number : 8920X
Immupharma PLC
30 June 2008
For Immediate Release 30 June 2008
ImmuPharma PLC
Annual Report and Accounts
In accordance with Rule 20 of the AIM Rules, ImmuPharma PLC (AIM:IMM), the specialist drug discovery and development company, confirms
that the... More...>> |
| 05/20/2008 | 3:25AM | TFNF | UK smallcap opening - ImmuPharma up on pre-clinical data
Buyers came for ImmuPharma, 12-1/2 pence up at
69, as the specialist drug discovery and development company disclosed that
cancer drug candidate IPP- 204106 shows complete response to tumours in multiple
human cancer cell lines.
Also on the upside, Alphameric edged ahead 1-1/2 to 20-1/2 after the
provider... More...>> |
| 05/20/2008 | 3:24AM | TFNF | ImmuPharma says pre-clinical data on new cancer drug positive
Drug discovery and development company
ImmuPharma Plc. said its pre-clinical data on its new cancer drug, IPP-204106
has shown complete response to tumours in multiple human cancer cell lines.
It said data on IPP-204106 confirmed the ability of the compounds to
effectively control and stop the growth of... More...>> |
| 05/20/2008 | 2:01AM | UKREG | Pre-clinical Data
RNS Number : 8204U
Immupharma PLC
20 May 2008
For Immediate Release 20 May 2008
ImmuPharma PLC
ImmuPharma's cancer drug candidate IPP- 204106 shows complete response to tumours in multiple human cancer cell lines
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company... More...>> |
| 05/13/2008 | 3:52AM | TFNF | Immupharma Lupus drug candidate IPP-201101 obtains trademark Lupuzor in U.S.
Drug discovery and development company
Immupharma Plc. said it has received approval of its trademark name Lupuzor for
its lead drug candidate for Lupus IPP-201101, by the US Patent and Trademark
Office.
The company said it has selected the trademark Lupuzor for use in
association with its peptide therapy... More...>> |
| 05/13/2008 | 2:00AM | UKREG | Trademark Approval
RNS Number : 2381U
Immupharma PLC
13 May 2008
For Immediate Release 13 May 2008
ImmuPharma PLC
Lupus drug candidate IPP-201101 obtains trademark LUPUZOR TM
ImmuPharma PLC (LSE:IMM), ("ImmuPharma" or the "Company"), the specialist drug discovery and development company... More...>> |